Skip to content

Growth and Tolerance of a Partially Hydrolyzed Infant Formula

Growth and Tolerance of a Partially Hydrolyzed Cow's Milk Protein (PHP) Infant Formula

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05047978
Enrollment
244
Registered
2021-09-17
Start date
2021-08-28
Completion date
2023-11-21
Last updated
2024-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Growth

Brief summary

The purpose of this research study is to compare the growth and tolerance of infants who consume either an infant formula with intact proteins or an infant formula with partially hydrolyzed proteins through approximately 12 months of age.

Interventions

OTHERCow's milk protein infant formula

A routine cow's milk-based infant formula

OTHERPartially hydrolyzed protein infant formula

A partially hydrolyzed cow's milk protein (PHP) infant formula

Sponsors

Mead Johnson Nutrition
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
10 Days to 14 Days
Healthy volunteers
Yes

Inclusion criteria

* 10 to 14 days of age at randomization * singleton birth * Gestational age of 37 to 42 weeks * Birth weight of 2500 g (5lbs 8oz or more) * Exclusively receiving infant formula for at least 24 hours prior to randomization * Parent or legal guardian has full intention to exclusively feed study formula through 120 days of age * Parent or legal guardian agrees not to enroll infant in another interventional clinical study while participating in this study * Signed informed consent and authorization to use and disclose Protected Health information

Exclusion criteria

* History of underlying metabolic or chronic disease * Evidence of feeding difficulties or history of formula intolerance * Weight at Visit 1 is \<98% of birth weight * Infant was born large for gestational age from a mother who was diabetic at childbirth * Infant is immunocompromised

Design outcomes

Primary

MeasureTime frame
Rate of body weight gainup to 120 days

Secondary

MeasureTime frameDescription
Pediatric Quality of Life Family Impact Moduleup to 365 days of agequestionnaire
Body lengthup to 365 days of age
Head circumferenceup to 365 days of age
Growth Z scoresup to 365 days of ageweight-for-age
Recall of study formula intake measured at each study visitup to 365 days of agequestionnaire
Recall of stool characteristics measured at each study visitup to 365 days of agequestionnaire
Medically confirmed adverse events collected throughout the study periodup to 365 days of age
Specific medically confirmed adverse events related to gastrointestinalup to 365 days of age
Specific medically confirmed adverse events related to allergyup to 365 days of age
Body weightup to 365 days of age
Pediatric Quality of Life Inventory Infant Scales120, 180, 275, and 365 days of ageQuestionnaire. A 5-point response scale is utilized (0 = never a problem; 4 = always a problem). Items are reverse-scored and linearly transformed to a 0-100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0), so that higher scores indicate better functioning (less negative impact).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026